Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05107219 · ClinicalTrials.gov registry record · Phase 1
GCC Agonist Signal in the Small Intestine
A Phase 1 study of Barrett Esophagus and Gastroesophageal Reflux Disease, sponsored by University of Wisconsin, Madison.
- Active
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 4
- Study locations
NCT05107219 is a Phase 1 study of Barrett Esophagus and Gastroesophageal Reflux Disease that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 43 participants, below the 3,564-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05107219, a Phase 1 study of Barrett Esophagus and Gastroesophageal Reflux Disease, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 4
- Study locations
Study Summary
This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy
- PROCEDURE Esophagogastroduodenoscopy
- DRUG Linaclotide
- DRUG Plecanatide
Study Locations (4)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Arizona
- Mayo Clinic in Arizona - Scottsdale
Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05107219
The ClinicalTrials.gov registry entry for NCT05107219 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,564-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (99% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Barrett Esophagus appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05107219 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, Arizona, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05107219 about?
NCT05107219 is a clinical study titled "GCC Agonist Signal in the Small Intestine". This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking eit...
What is the current status of trial NCT05107219?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-11-30. Estimated completion is 2026-02-28.
What conditions does trial NCT05107219 study?
This clinical trial studies the following conditions: Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm.
What interventions are being tested in trial NCT05107219?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Biopsy (PROCEDURE), Esophagogastroduodenoscopy (PROCEDURE), Linaclotide (DRUG), Plecanatide (DRUG).
Who is sponsoring clinical trial NCT05107219?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05107219 being conducted?
This trial has 4 study locations across Arizona, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barrett Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
-
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RECRUITING
-
Longitudinal Oral Microbiome Sampling for BE
RECRUITING
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.